Get started
Abeona Therapeutics Inc.Abeona Therapeutics Inc.Abeona Therapeutics Inc.

Abeona Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ABEO chart


Full chart

ABEO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪259.96 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.25 USD
Net income (FY)
‪−54.19 M‬ USD
Revenue (FY)
‪3.50 M‬ USD
Shares float
‪39.34 M‬
Beta (1Y)
0.02

Employees


Employees (FY)
84
Change (1Y)
+27 +47.37%
Revenue / Employee (1Y)
‪41.67 K‬ USD
Net income / Employee (1Y)
‪−645.10 K‬ USD

About Abeona Therapeutics Inc.


Sector
Health Technology
CEO
Vishwas Seshadri
Headquarters
Cleveland
Website
abeonatherapeutics.com
Founded
1974
FIGI
BBG000DT5D52
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ABEO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ABEO is 5.98 USD — it has increased by 3.28% in the past 24 hours. Watch Abeona Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Abeona Therapeutics Inc. stocks are traded under the ticker ABEO.
ABEO stock has risen by 0.50% compared to the previous week, the month change is a −8.84% fall, over the last year Abeona Therapeutics Inc. has showed a 42.38% increase.
We've gathered analysts' opinions on Abeona Therapeutics Inc. future price: according to them, ABEO price has a max estimate of 21.00 USD and a min estimate of 9.50 USD. Watch ABEO chart and read a more detailed Abeona Therapeutics Inc. stock forecast: see what analysts think of Abeona Therapeutics Inc. and suggest that you do with its stocks.
ABEO reached its all-time high on May 22, 1981 with the price of 5,437,500.00 USD, and its all-time low was 2.19 USD and was reached on Feb 24, 2023. View more price dynamics on ABEO chart.
See other stocks reaching their highest and lowest prices.
ABEO stock is 7.12% volatile and has beta coefficient of 0.02. Track Abeona Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Abeona Therapeutics Inc. there?
Today Abeona Therapeutics Inc. has the market capitalization of ‪259.96 M‬, it has decreased by −1.19% over the last week.
Yes, you can track Abeona Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Abeona Therapeutics Inc. is going to release the next earnings report on Mar 24, 2025. Keep track of upcoming events with our Earnings Calendar.
ABEO earnings for the last quarter are −0.63 USD per share, whereas the estimation was −0.39 USD resulting in a −60.51% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about Abeona Therapeutics Inc. earnings.
Abeona Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪100.00 K‬ USD. In the next quarter, revenue is expected to reach ‪100.00 K‬ USD.
ABEO net income for the last quarter is ‪−30.27 M‬ USD, while the quarter before that showed ‪7.41 M‬ USD of net income which accounts for −508.71% change. Track more Abeona Therapeutics Inc. financial stats to get the full picture.
No, ABEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 84.00 employees. See our rating of the largest employees — is Abeona Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Abeona Therapeutics Inc. EBITDA is ‪−56.91 M‬ USD, and current EBITDA margin is ‪−1.29 K‬%. See more stats in Abeona Therapeutics Inc. financial statements.
Like other stocks, ABEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Abeona Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Abeona Therapeutics Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Abeona Therapeutics Inc. stock shows the neutral signal. See more of Abeona Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.